33 related articles for article (PubMed ID: 38708333)
1. Cholangiocarcinoma diagnosis and treatment.
Editorial Office of Asian Biomedicine
Asian Biomed (Res Rev News); 2024 Apr; 18(2):35-36. PubMed ID: 38708331
[No Abstract] [Full Text] [Related]
2. Treatment of cholangiocarcinoma by pGCsiRNA-vascular endothelial growth factor in vivo.
Lu S; Li J
Asian Biomed (Res Rev News); 2024 Apr; 18(2):61-68. PubMed ID: 38708333
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.
Xiao K; Ouyang Z; Tang HH
Oncol Lett; 2018 Aug; 16(2):1841-1848. PubMed ID: 30008874
[TBL] [Abstract][Full Text] [Related]
4. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
5. [Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer].
Hu ZL; Wen JF; Shen M; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):70-4. PubMed ID: 16562680
[TBL] [Abstract][Full Text] [Related]
6. Influence of Photodynamic Therapy on Apoptosis and Invasion of Human Cholangiocarcinoma QBC939 Cell Line.
Chen YJ; Jiang HT; Cao JY
Chin Med Sci J; 2015 Dec; 30(4):252-9. PubMed ID: 26960307
[TBL] [Abstract][Full Text] [Related]
7. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.
Fava G; Demorrow S; Gaudio E; Franchitto A; Onori P; Carpino G; Glaser S; Francis H; Coufal M; Marucci L; Alvaro D; Marzioni M; Horst T; Mancinelli R; Benedetti A; Alpini G
Liver Int; 2009 Aug; 29(7):1031-42. PubMed ID: 19291182
[TBL] [Abstract][Full Text] [Related]
8. IDO2-siRNA Carried by
Zhao T; Guo M; Chen H; Zhou L; Guo J; Liu S; Wang Z; Huang W; Zhang Q; Zhong J; Wang M; Jia H; Zhang Y
Curr Mol Pharmacol; 2023; 16(8):881-893. PubMed ID: 36999419
[TBL] [Abstract][Full Text] [Related]
9. Circular RNAs in cholangiocarcinoma.
Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y
Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149
[TBL] [Abstract][Full Text] [Related]
10. The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Cai C; Wang X; Fu Q; Chen A
World J Surg Oncol; 2022 Feb; 20(1):40. PubMed ID: 35189920
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.
Yang Z; Shi G
Cancer Med; 2022 Feb; 11(3):692-704. PubMed ID: 34862762
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Intrahepatic Cholangiocarcinoma - Review.
Bekki Y; Von Ahrens D; Takahashi H; Schwartz M; Gunasekaran G
Front Oncol; 2021; 11():776863. PubMed ID: 34746017
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
